178 related articles for article (PubMed ID: 27852271)
21. A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
[TBL] [Abstract][Full Text] [Related]
22. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.
Sunami K; Ichikawa H; Kubo T; Kato M; Fujiwara Y; Shimomura A; Koyama T; Kakishima H; Kitami M; Matsushita H; Furukawa E; Narushima D; Nagai M; Taniguchi H; Motoi N; Sekine S; Maeshima A; Mori T; Watanabe R; Yoshida M; Yoshida A; Yoshida H; Satomi K; Sukeda A; Hashimoto T; Shimizu T; Iwasa S; Yonemori K; Kato K; Morizane C; Ogawa C; Tanabe N; Sugano K; Hiraoka N; Tamura K; Yoshida T; Fujiwara Y; Ochiai A; Yamamoto N; Kohno T
Cancer Sci; 2019 Apr; 110(4):1480-1490. PubMed ID: 30742731
[TBL] [Abstract][Full Text] [Related]
23. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations.
Allegretti M; Fabi A; Buglioni S; Martayan A; Conti L; Pescarmona E; Ciliberto G; Giacomini P
J Exp Clin Cancer Res; 2018 Mar; 37(1):47. PubMed ID: 29506529
[TBL] [Abstract][Full Text] [Related]
24. Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene Testing.
Hiemenz MC; Kadauke S; Lieberman DB; Roth DB; Zhao J; Watt CD; Daber RD; Morrissette JJ
PLoS One; 2016; 11(4):e0152851. PubMed ID: 27043212
[TBL] [Abstract][Full Text] [Related]
25. Clinical target sequencing for precision medicine of breast cancer.
Tsuchida J; Rothman J; McDonald KA; Nagahashi M; Takabe K; Wakai T
Int J Clin Oncol; 2019 Feb; 24(2):131-140. PubMed ID: 30604156
[TBL] [Abstract][Full Text] [Related]
26. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
27. The clinical utility of molecular genetic cancer profiling.
Joseph L
Expert Rev Mol Diagn; 2016 Aug; 16(8):827-38. PubMed ID: 27253039
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
29. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
[TBL] [Abstract][Full Text] [Related]
30. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
31. Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies.
Bruinooge SS; Sherwood S; Grubbs S; Schilsky RL
J Oncol Pract; 2019 Nov; 15(11):575-583. PubMed ID: 31386607
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories.
Mendez P; Dang J; Kim JW; Lee S; Yoon JH; Kim T; Sailey CJ; Jablons DM; Kim IJ
Int J Oncol; 2016 Jul; 49(1):235-42. PubMed ID: 27121194
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive genomic sequencing and the molecular profiles of clinically advanced breast cancer.
Ross JS; Gay LM
Pathology; 2017 Feb; 49(2):120-132. PubMed ID: 28034454
[TBL] [Abstract][Full Text] [Related]
34. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Flaherty KT; Gray RJ; Chen AP; Li S; McShane LM; Patton D; Hamilton SR; Williams PM; Iafrate AJ; Sklar J; Mitchell EP; Harris LN; Takebe N; Sims DJ; Coffey B; Fu T; Routbort M; Zwiebel JA; Rubinstein LV; Little RF; Arteaga CL; Comis R; Abrams JS; O'Dwyer PJ; Conley BA;
J Clin Oncol; 2020 Nov; 38(33):3883-3894. PubMed ID: 33048619
[TBL] [Abstract][Full Text] [Related]
35. Clinical application of amplicon-based next-generation sequencing in cancer.
Chang F; Li MM
Cancer Genet; 2013 Dec; 206(12):413-9. PubMed ID: 24332266
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
Kikuchi J; Ohhara Y; Takada K; Tanabe H; Hatanaka K; Amano T; C Hatanaka K; Hatanaka Y; Mitamura T; Kato M; Shibata Y; Yabe I; Endoh A; Komatsu Y; Matsuno Y; Sugiyama M; Manabe A; Sakurai A; Takahashi M; Naruse H; Torimoto Y; Dosaka-Akita H; Kinoshita I
Jpn J Clin Oncol; 2021 Apr; 51(5):753-761. PubMed ID: 33532831
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
38. Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing.
Patel NM; Michelini VV; Snell JM; Balu S; Hoyle AP; Parker JS; Hayward MC; Eberhard DA; Salazar AH; McNeillie P; Xu J; Huettner CS; Koyama T; Utro F; Rhrissorrakrai K; Norel R; Bilal E; Royyuru A; Parida L; Earp HS; Grilley-Olson JE; Hayes DN; Harvey SJ; Sharpless NE; Kim WY
Oncologist; 2018 Feb; 23(2):179-185. PubMed ID: 29158372
[TBL] [Abstract][Full Text] [Related]
39. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Syn NL; Yong WP; Goh BC; Lee SC
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
[TBL] [Abstract][Full Text] [Related]
40. Impact of tumor sequencing on the use of anticancer drugs.
Thomas F; Desmedt C; Aftimos P; Awada A
Curr Opin Oncol; 2014 May; 26(3):347-56. PubMed ID: 24709974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
